Treatment of Chronic Lymphocytic Leukemia with Kinase inhibitors blocking B-cell receptor signaling and the BCL2 (B-cell lymphoma 2) antagonist venetoclax

posted in: Pediatric News | 0

Treatment of Chronic Lymphocytic Leukemia with Kinase inhibitors blocking B-cell receptor signaling and the BCL2 (B-cell lymphoma 2) antagonist venetoclax

J.A. Burger

Kinase inhibitors blocking B-cell receptor signaling and the BCL2 (B-cell lymphoma 2) antagonist venetoclax have been introduced and are fundamentally changing the chronic lymphocytic leukemia (CLL) treatment landscape.